Literature DB >> 29504817

Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET).

Jacqueline Trouillas1,2, Gérald Raverot2,3,4.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29504817      PMCID： PMC6103703          DOI： 10.1080/15384101.2018.1442139

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

Authors:  S L Asa; O Casar-Borota; P Chanson; E Delgrange; P Earls; S Ezzat; A Grossman; H Ikeda; N Inoshita; N Karavitaki; M Korbonits; E R Laws; M B Lopes; N Maartens; I E McCutcheon; O Mete; H Nishioka; G Raverot; F Roncaroli; W Saeger; L V Syro; A Vasiljevic; C Villa; A Wierinckx; J Trouillas
Journal:  Endocr Relat Cancer       Date:  2017-04       Impact factor: 5.678

2.  Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.

Authors:  Marie Chanal; Pascale Chevallier; Véronique Raverot; Guillaume Fonteneau; Kristin Lucia; Jose Luis Monteserin Garcia; Alexa Rachwan; Emmanuel Jouanneau; Jacqueline Trouillas; Jérôme Honnorat; Carole Auger; Marily Theodoropoulou; Gérald Raverot
Journal:  Mol Cancer Ther       Date:  2016-03-16       Impact factor: 6.261

3.  Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.

Authors:  Rocío Sotillo; Oliver Renner; Pierre Dubus; Jesús Ruiz-Cabello; Juan Martín-Caballero; Mariano Barbacid; Amancio Carnero; Marcos Malumbres
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 4.  Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.

Authors:  Gerald Raverot; Emmanuel Jouanneau; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2014-03-13       Impact factor: 6.664

5.  HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Authors:  Monica Fedele; Orlando Paciello; Davide De Biase; Mario Monaco; Gennaro Chiappetta; Michela Vitiello; Antonio Barbieri; Domenica Rea; Antonio Luciano; Serenella Papparella; Claudio Arra; Alfredo Fusco
Journal:  Cell Cycle       Date:  2018-01-30       Impact factor: 4.534

6.  Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas.

Authors:  Monica Fedele; Sabrina Battista; Lawrence Kenyon; Gustavo Baldassarre; Vincenzo Fidanza; Andres J P Klein-Szanto; A F Parlow; Rosa Visone; Giovanna M Pierantoni; Eric Outwater; Massimo Santoro; Carlo M Croce; Alfredo Fusco
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

7.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

Authors:  Ann McCormack; Olaf M Dekkers; Stephan Petersenn; Vera Popovic; Jacqueline Trouillas; Gerald Raverot; Pia Burman
Journal:  Eur J Endocrinol       Date:  2018-01-12       Impact factor: 6.664
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.